| |
| | December 04, 2006
Leading Virologist Dr. Clive Patience Appointed to Help Guide the Development of Sernova's Proposed Diabetes Product
|
| | Kelowna, B.C. -- Sernova Corp. ("Sernova") is pleased to announce that Dr. Clive Patience Ph.D. has joined its Scientific Advisory Board ("SAB") to assist the company with its diabetes product development.
"Dr. Patience is one of the world's leading experts on biological safety of xenotransplantation, and is a supporter of Sernova's emerging diabetes technology." stated Dr. David White, Chair of Sernova's SAB. "Our research team will be enhanced by his intimate understanding of biological safety, while his knowledge of the FDA process will assist us in moving this technology to the clinic."
Dr. Patience is currently the Associate Director of Bioanalytical Quality Control at Biogen Idec. Inc. (NASDAQ: BIIB) in Cambridge Massachusetts. For several years previously he directed research on porcine retroviruses and herpesviruses, and in a 3 year study demonstrated the acceptable microbiological safety of pig to non-human primate transplants. He has also been an invited speaker to FDA safety committees..
About Dr. Patience
Dr. Patience obtained his Ph.D in virology from the University of London while working as a research scientist at the Institute of Cancer Research in London England, Much of his research focused on the biology of HIV, porcine endogenous retroviruses, and retroviral/adenoviral gene therapy vectors. He later accepted a position in Massachusetts as Director of Microbiological Safety with Immerge Bio Therapeutics, a world leader in research to genetically modify pigs for organ transplants. In 2004 he joined Biogen Idec as a Senior Scientist before ascending to his current position. His research has been published in many peer reviewed journals including Nature Medicine, the Journal of Virology and the American Journal of Transplantation. Dr. Patience has also contributed chapters to several medical books.
About Sernova
Sernova Corp. is a Canadian based, health sciences company focused on commercializing medical technologies and currently working to cure insulin dependent diabetes. According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. Over $100 billion per year is spent in the US on treating diabetes and its complications.
This news release may contain forward-looking statements. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.
ON BEHALF OF THE BOARD
"Justin Leushner"
Justin Leushner, President
For further information contact:
TEL: (888) 318-7062
FAX: (250) 868-8493
info@sernovacorp.com
www.sernovacorp.com
Phil Morehouse
Executive Vice President
Sernova Corp.
THE TSX VENTURE EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NEWS RELEASE. |
| |
| | You can view the Next News Releases item: Tue Dec 19, 2006, Results of Toronto Hospital Study of Diabetic Mice Supports Sernova Corp's Cellular Therapy Technology
You can view the Previous News Releases item: Fri Dec 1, 2006, Breakthrough Magnetic Resonance Imaging Technique Developed for Diabetes's Cellular Therapy: Published in November Issue of Medical Journal, "Diabetes"
You can return to the main News Releases page, or press the Back button on your browser.
|
| |
